BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16689336)

  • 1. [Osteoporosis].
    Chaki O
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():370-4. PubMed ID: 16689336
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent advance in basic research for osteoporosis].
    Suda T; Miyaura C
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():13-20. PubMed ID: 15035090
    [No Abstract]   [Full Text] [Related]  

  • 3. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
    Yeung RS
    J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of the immune system in the pathophysiology of osteoporosis.
    Clowes JA; Riggs BL; Khosla S
    Immunol Rev; 2005 Dec; 208():207-27. PubMed ID: 16313351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
    Ferrer Cañabate J; Tovar I; Martínez P
    An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
    [No Abstract]   [Full Text] [Related]  

  • 6. [Molecular mechanism of bone metabolism].
    Kotake S; Utagawa N; Suda T; Kamatani N
    Nihon Naika Gakkai Zasshi; 2000 Oct; 89(10):2046-53. PubMed ID: 11215116
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
    Tanaka S; Nakamura K; Takahasi N; Suda T
    Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis.
    Hofbauer LC; Heufelder AE; Erben RG
    J Rheumatol; 2001 Apr; 28(4):685-7. PubMed ID: 11327234
    [No Abstract]   [Full Text] [Related]  

  • 9. [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases].
    Hofbauer LC; Heufelder AE
    Dtsch Med Wochenschr; 2001 Feb; 126(6):145-50. PubMed ID: 11233883
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical implications of new insights into the regulation of bone resorption].
    Lems WF; Bijlsma JW
    Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3.
    Voskaridou E; Terpos E
    Eur J Haematol; 2005 Apr; 74(4):359-61. PubMed ID: 15777350
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
    Hofbauer LC
    Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence of a role for RANKL in the development of myeloma bone disease.
    De Leenheer E; Mueller GS; Vanderkerken K; Croucher PI
    Curr Opin Pharmacol; 2004 Aug; 4(4):340-6. PubMed ID: 15251126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
    Anandarajah AP; Schwarz EM
    J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANK ligand and the regulation of skeletal remodeling.
    Bell NH
    J Clin Invest; 2003 Apr; 111(8):1120-2. PubMed ID: 12697730
    [No Abstract]   [Full Text] [Related]  

  • 18. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
    Cozzani M; Giovannini I; Naccari R; Penolazzi L; Lambertini E; Borgatti M; Piva R; Gambari R; Siciliani G
    Prog Orthod; 2005; 6(2):238-47. PubMed ID: 16276433
    [No Abstract]   [Full Text] [Related]  

  • 19. [Osteoclast-activating factors (OAF)].
    Sato K
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():228-31. PubMed ID: 15658306
    [No Abstract]   [Full Text] [Related]  

  • 20. [Merger of bone biology and immunology].
    Suda T; Shima N; Higashio K
    Tanpakushitsu Kakusan Koso; 2002 Oct; 47(13):1837-43. PubMed ID: 12385106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.